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Abstract
Purpose: To provide practice recommendations for the diagnosis and management of hypoparathyroidism in adults.
Methods: Key questions pertaining to the diagnosis and management of hypoparathyroidism were addressed following 
a literature review. We searched PubMed, MEDLINE, EMBASE and Cochrane databases from January 2000 to March 
2018 using keywords ‘hypoparathyroidism, diagnosis, treatment, calcium, PTH, calcidiol, calcitriol, hydrochlorothiazide 
and pregnancy’. Only English language papers involving humans were included. We excluded letters, reviews 
and editorials. The quality of evidence was evaluated based on the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach. These standards of care for hypoparathyroidism have been endorsed 
by the Canadian Society of Endocrinology and Metabolism.
Results: Hypoparathyroidism is a rare disease characterized by hypocalcemia, hyperphosphatemia and a low or 
inappropriately normal serum parathyroid hormone level (PTH). The majority of cases are post-surgical (75%) with 
nonsurgical causes accounting for the remaining 25% of cases. A careful review is required to determine the etiology 
of the hypoparathyroidism in individuals with nonsurgical disease. Hypoparathyroidism is associated with significant 
morbidity and poor quality of life. Treatment requires close monitoring as well as patient education. Conventional 
therapy with calcium supplements and active vitamin D analogs is effective in improving serum calcium as well as in 
controlling the symptoms of hypocalcemia. PTH replacement is of value in lowering the doses of calcium and active 
vitamin D analogs required and may be of value in lowering long-term complications of hypoparathyroidism. This 
manuscript addresses acute and chronic management of hypoparathyroidism in adults.
Main conclusions: Hypoparathyroidism requires careful evaluation and pharmacologic intervention in order to improve 
serum calcium and control the symptoms of hypocalcemia. Frequent laboratory monitoring of the biochemical profile 
and patient education is essential to achieving optimal control of serum calcium.
Introduction
Hypoparathyroidism is an uncommon disorder that is 
characterized by hypocalcemia and hyperphosphatemia 
due to low or inappropriately normal serum levels of 
parathyroid hormone (PTH). The most common cause of 
hypoparathyroidism is neck surgery, (75% of the cases) 
during which parathyroid glands are inadvertently injured, 
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removed or deprived of their blood supply. The causes 
of nonsurgical hypoparathyroidism which comprise the 
remaining 25% of the cases are listed in Table  1. PTH 
resistance syndromes have the same biochemical profile 
as hypoparathyroidism however PTH levels are elevated.
Conventional therapy of hypoparathyroidism 
consists of the use of calcium supplements, and active 
vitamin D. This therapeutic approach addresses the 
hypocalcemia of hypoparathyroidism, but fails to 
provide a physiologic replacement for the lack of PTH. 
Replacement therapy with recombinant human PTH 
(rhPTH(1–84)) is now approved in the United States and 
Europe as an adjunctive treatment for adult patients 
with chronic hypoparathyroidism who cannot be well 
controlled on conventional therapy management of 
hypoparathyroidism during pregnancy is challenging 
with very limited data currently available to guide 
clinical practice. Canadian Endocrine Update, McMaster 
University, Western University and the Mayo Clinic formed 
a working group comprising of parathyroid experts as well 
as general endocrinologists. Key questions addressing the 
diagnosis and management of hypoparathyroidism were 
addressed following an extensive review of the literature. 
These recommendations reflect current evidence and 
consensus regarding the appropriate standard of care 
today. These practice recommendations are to be 
applied in the context of clinical care with appropriate 
adjustments for comorbidities, individual preferences as 
well as other patient factors. They do not preclude clinical 
judgment and reflect the limited clinical trial evidence 
available today.
Methodology
We searched PubMed, MEDLINE, EMBASE and Cochrane 
databases from January 2000 to March 2018 using keywords 
‘hypoparathyroidism, diagnosis, treatment, calcium, PTH, 
calcidiol, calcitriol, hydrochlorothiazide and pregnancy’. 
MeSH terms were utilized in various combinations to 
increase search sensitivity. The search strategy was adapted 
to PubMed to search for articles published ahead of print 
(Figure 1). Of the 482 citations, we included only English 
language papers involving humans. We excluded letters, 
reviews and editorials. As evidence is limited for certain 
questions being addressed, we included case reports and case 
series. Evaluation of the quality of evidence was performed 
based on the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach (1) 
(Table 2). Papers were identified by content experts (A K and 
B C). Landmark papers published earlier then 2000 were also 
included if the findings have not been superseded by more 
recent data. All co-authors contributed to the development 
of this standards paper. The key questions, results of the 
literature review and practice recommendations were 
presented at the Endocrine Society annual meeting 
in March 2018 in a symposium session entitled ‘2018 
Parathyroid Summit: A Focus on Hypoparathyroidism.’ 
The session included time for attendee feedback, which was 
incorporated into the current manuscript.
This concise document outlines acceptable care today 
based on current evidence and consensus. We provide 
tables and tools to simplify, enhance and standardize 
treatment.
Table 1 Causes of nonsurgical hypoparathyroidism.
 • Autoimmune
 • Genetic variants
 • Infiltrative
 • Metastatic
 • Radiation destruction
 • Mineral deposition (copper or iron)
 • Functional (magnesium deficiency or excess)
 • Transient (burn injuries, acute illness)
 • PTH resistance states
 • Maternal hyperparathyroidism
 • Idiopathic
Figure 1
Flow diagram.
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1. Confirming a diagnosis of 
hypoparathyroidism and evaluating target 
organ damage
(a) How is chronic hypoparathyroidism diagnosed?
In patients with history of thyroid, parathyroid, 
laryngeal or other neck surgeries, the temporal proximity 
of the surgical procedure to the development of 
hypocalcemia, as well as the duration of hypocalcemia, 
will determine whether this is acute and/or transient 
hypoparathyroidism (surgery <6 months prior) or chronic 
and permanent hypoparathyroidism (surgery >6 months 
prior) (2, 3, 4, 5, 6, 7). A low serum albumin-adjusted 
calcium <2.0 mmol/L or <8 mg/dL in the presence of 
a low PTH <15 pg/mL is associated with a high risk of 
permanent hypoparathyroidism and requires appropriate 
supplementation with calcium and active vitamin D 
metabolites and follow-up (8, 9).
Hypocalcemia for six or more months after surgery, 
with or without symptoms in the presence of a low or 
inappropriately normal PTH is diagnostic of permanent 
surgical hypoparathyroidism. Classic symptoms of 
hypoparathyroidism principally reflect the effects 
of hypocalcemia, and may involve neuromuscular, 
neurologic, behavioral/psychiatric and cardiovascular 
systems and include numbness and tingling in face, 
hands or feet, muscle cramping, twitching, depression, 
irritability, confusion, seizures, bradyarrythmias, 
wheezing and laryngospasm. Laboratory testing should 
confirm a low albumin-corrected total serum calcium 
level or a low ionized calcium levels and low PTH on 
at least two occasions (emergent care for hypocalcemia 
should not be delayed and does not require two test 
results for confirmation of hypocalcemia). If the PTH is 
in the normal reference range and is not elevated in the 
presence of hypocalcemia, this would also be indicative of 
impaired parathyroid response to the hypocalcemic insult 
and diagnostic of hypoparathyroidism (3). In nonsurgical 
patients, obtaining the family history is essential along 
with assessing other clinical features that are part of 
complex syndromes in which hypoparathyroidism is a 
component (4, 5). Genetic testing is available to diagnose 
the molecular basis for the disorder (Table 3).
Nonsurgical causes of hypoparathyroidism
1. Autoimmune hypoparathyroidism
Autoimmune hypoparathyroidism is the most common 
cause of nonsurgical hypoparathyroidism. It may occur 
in isolation or as part of the autoimmune polyendocrine 
syndrome1 (APS1). APS1 is caused by mutations in the 
autoimmune regulator gene (AIRE), which is expressed in 
the lymph nodes, thymus, pancreas, adrenal cortex and 
fetal liver (10, 11).
APS1 is associated with circulating autoantibodies 
and infiltration of the involved organs with lymphocytes 
resulting in organ failure. APS1 is characterized by three 
major clinical features: chronic mucocutaneous candidiasis, 
hypoparathyroidism and adrenal insufficiency. More than 
80% of APS1 patients have hypoparathyroidism, and this 
may be the only endocrinopathy present (12, 13).
Patients may have in addition more than 20 minor 
clinical features (3, 5) (Table 4). The diagnosis of APS1 is 
probable in the presence of at least one major syndrome 
and positive antibodies to type 1 interferons, which 
are present in >95% of patients (12). Autoantibodies to 
21-hydroxylase correlate with the development of adrenal 
Table 2 Quality assessment criteria (1).
Study design Quality of evidence Lower if Higher if
Randomized trial High Risk of bias Large effect
(−1) Serious (+1) Large
(−2) Very serious (+2) Very large
Moderate Inconsistency Dose response
(−1) Serious (+1) Evidence of a gradient
(−2) Very serious
Observational study Low Indirectness All plausible confounding
(−1) Serious (+1) Would reduce a demonstrated effect or
(−2) Very serious
Very low Imprecision (+1) Would suggest a spurious effect when results show no effect
(−1) Serious
(−2) Very serious
Publication bias
(−1) Likely
(−2) Very likely
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Table 3 Genetic causes of hypoparathyroidism – key clinical findings and lab tests.
Disorder
Clinical or laboratory features prompting 
consideration of specific genetic or other 
types of testing Molecular defect
Genetic and other testing to 
establish diagnosis
Autosomal dominant 
hypoparathyroidism 
(ADH) type 1 and 2
Typically asymptomatic or mild 
hypocalcemia with or without 
hypercalciuria (ADH types 1 and 2)
Gain of function 
mutation in CASR 
(type 1) or G alpha 
11 (type 2)
CASR or GNA11 sequencing
ADH type 1 with Bartter’s 
syndrome type 5
Hypocalcemia, hypomagnesemia, 
hypokalemia, alkalosis, hypercalciuria, 
and salt and water depletion may be 
seen depending on the severity
CASR CASR sequencing
Isolated 
hypoparathyroidism
Presentation dominated by biochemical 
and clinical features of 
hypoparathyroidism
PTH, GCM2, sequencing 
depending on presentation
 Autosomal recessive PTH or GCM2
 Autosomal dominant PTH or GCM2
 X-linked recessive SOX3 locus (in 
males)
Hypoparathyroidism of 
autoimmune etiology
Autoimmune mediated
Autoimmune 
polyendocrine syndrome 
type 1 (APS1)
Isolated
Other autoimmune diseases and features 
such as mucocutaneous candidiasis, 
adrenal insufficiency and hypogonadism
May show only hypoparathyroidism
Usually due to 
homozygous 
mutations in AIRE
AIRE mutations or of 
unknown etiology
AIRE sequencing
Presence of 21-hydroxylase 
antibodies supports diagnosis 
of autoimmune adrenal 
insufficiency
Testing for other hormonal 
insufficiency states (e.g., 
adrenal and gonadal 
insufficiency)
AIRE sequencing
Hypoparathyroidism, 
deafness, renal 
anomalies (HDR) 
syndrome
Sensorineural deafness, renal anatomic 
abnormalities and renal dysfunction, 
autosomal dominant inheritance
GATA3 GATA3 sequencing, hearing 
testing, renal imaging
DiGeorge syndrome Cardiac defects (present in ~80% including 
ventriculoseptal defect, tetralogy of 
Fallot, interrupted aortic arch, truncus 
arteriosus), immunodeficiency 
(recurrent infections, thymic hypoplasia 
or aplasia, T cell lymphopenia), 
hypoparathyroidism, pharyngeal and 
laryngeal abnormalities, cleft palate, 
behavioral and psychiatric problems, 
ophthalmic anomalies, hearing loss
Variety of defects 
and deletions and 
microdeletions in 
chromosome 
22q11.2
Fluorescence in situ 
hybridization (FISH) is the 
traditional test most 
commonly done
Two other diagnostic 
approaches are used with 
greater frequency than FISH 
including PCR-based multiplex 
ligation-dependent probe 
amplification and SNP) array. 
In some case, TBX sequencing 
is done
Kenny–Caffey syndrome
 Type 1 or Sanjad–Sakati 
syndrome (autosomal 
recessive)
Short stature, growth retardation, small 
hands and feet, cortical thickening and 
medullary stenosis of the long bones, 
delayed fontanelle closure, abnormal 
eyes, dysmorphic facies, 
hypoparathyroidism
TBCE TBCE sequencing
 Type 2 (autosomal 
dominant) 
 
 
Gracile bone dysplasia, short stature with 
cortical thickening and medullary 
stenosis of tubular bones, delayed 
closure of anterior fontanelle, eye 
abnormalities, and hypoparathyroidism
FAM111A 
 
 
 
FAM111A sequencing 
 
 
 
(Continued)
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insufficiency and antibodies to NALP5 correlate with the 
development of hypoparathyroidism and measuring these 
antibodies can be of value in predicting the development 
of adrenal insufficiency and hypoparathyroidism 
respectively A molecular diagnosis can be confirmed with 
DNA studies of the AIRE gene (14).
Activating antibodies to the calcium-sensing receptor 
can suppress PTH secretion leading to hypoparathyroidism 
(15). Antibodies against the extracellular domain of 
the CASR have been identified in individuals with 
autoimmune hypoparathyroidism (16).
2. Genetic variants
Genetic causes of hypoparathyroidism is presented in 
Table 3.
A. Isolated hypoparathyroidism
a. Glial cells missing (GCM2) gene mutation results 
in isolated hypoparathyroidism with early onset of 
hypoparathyroidism due to parathyroid gland agenesis (17).
b. Autosomal dominant hypocalcemia (ADH).
Type 1 is caused by an activating mutation in the 
calcium-sensing receptor (CASR) gene which increases 
the sensitivity of the CASR to extracellular ionized 
calcium. The mutated receptor is expressed in the 
parathyroid glands causing suppression of PTH synthesis 
and secretion at normal ionized calcium levels leading 
to hypoparathyroidism (17). In the kidney, the mutated 
receptor results in enhanced urine calcium losses 
with relative hypercalciuria and an increased risk of 
nephrocalcinosis and nephrolithiasis.
Type 2 is caused by an activating mutation in the 
guanine nucleotide-binding protein alpha 11 (GNA11) 
gene encoding the alpha subunit of the G protein G11 – a 
key mediator of CASR signaling resulting in suppresion 
of PTH even at low serum calcium levels (18,19). Urine 
calcium excretion is not affected in type 2 ADH (20).
c. PTH gene mutations:
Rare mutations in the PTH gene located on locus 
11p15 have been associated with defective synthesis and 
secretion of PTH (21).
Disorder
Clinical or laboratory features prompting 
consideration of specific genetic or other 
types of testing Molecular defect
Genetic and other testing to 
establish diagnosis
Hypoparathyroidism 
associated with 
mitochondrial disorders
Mutations in the 
mitochondrial 
genome
Mitochondrial DNA sequencing
Kearns Sayre syndrome Ophthalmoplegia, retinal pigmentary and 
cardiac conduction abnormalities, 
proximal and bulbar weakness, possibly 
ataxia
mtDNA large-scale 
deletion
Specialized clinical assessments 
depending on the 
manifestations (cardiac, 
ophthalmologic, neurologic, 
endocrinologic and others)
 MELAS Encephalomyopathy, lactic acidosis, and 
stroke-like episodes along with external 
ophthalmoplegia, diabetes, hearing loss, 
early-onset stroke symptoms, migraine, 
and cognitive dysfunction
Mutations in the 
mitochondrial 
tRNA Leu gene
 MTPDS Disordered fatty acid oxidation associated 
with neuropathy, retinopathy and fatty 
liver
Mutations in 
mitochondrial 
genome
AIRE, autoimmune regulator of endocrine function; CASR, calcium-sensing receptor; GNA11; G protein alpha subunit 11; MELAS, mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like syndrome; MTPDS, mitochondrial trifunctional protein deficiency.
Table 4 Features of APS1.
Major features
 • Mucocutaneous candidiasisHypoparathyroidism
 • Adrenal insufficiency
Minor features
 • KeratitisAutoimmune hepatitis
 • Primary ovarian failure
 • Enamel hypoplasia
 • Enteropathy with chronic diarrhea or constipation
 • Photophobia
 • Periodic fever with rash
 • Pneumonitis
 • Nephritis
 • Pancreatitis
 • T1DM
 • Functional asplenia
 • Celiac disease
 • Thyroiditis
 • Retinitis
 • Pure red-cell aplasia
 • Polyarthritis
Table 3 Continued.
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B. Hypoparathyroidism with additional features (Table 3)
a. DiGeorge syndrome is a rare condition affecting 1/4000–
5000 live births, 70–80% carry a microdeletion within 
22q.21–q11.23 chromosome. The clinical features include 
developmental delay, palatal anomalies, parathyroid 
aplasia or hypoplasia causing neonatal hypocalcemia, 
aplastic or hyoplastic thymus with immune deficits, 
congenital heart defects, facial anomalies, speech and 
learning disabilities (22, 23, 24).
b. Hypoparathyroidism, sensorineural deafness and renal 
dysplasia syndrome (HDR syndrome).
This is a rare autosomal dominant disorder associated 
with mutations or deletions in the GATA-binding protein 
3 gene localized to chromosomal region 10p14–15 
resulting in haploinsufficiency of the transcription factor 
GATA 3, a protein critical for normal parathyroid, kidney 
and otic vesicle development. The presentation includes 
the presence of hypocalcemia, hearing loss and renal 
disease (25, 26).
c. Hypoparathyroidism–retardation–dysmorphism (HRD) 
syndrome. HRD syndrome is a rare form of autosomal 
recessive hypoparathyroidism which encompasses the two 
syndromes namely the Sanjad–Sakati and the Kenney Caffey 
syndromes type 1 and type 2. The clinical features include 
congenital hypoparathyroidism, severe growth impairment, 
mental retardation and facial dimorphism (27, 28, 29).
3. Infiltrative causes
Destruction of the parathyroid glands secondary to 
granulomatous infiltration (e.g. sarcoidosis, amyloidosis, 
Riedel’s thyroiditis) has been reported (30, 31, 32, 33, 34).
4. Metastatic cancer
Infiltrating secondary tumors very rarely cause 
hypoparathyroidism. The most common tumors are breast, 
leukemia, skin, lung, sarcomas and lymphomas (35).
5. Radiation destruction
Rarely high doses of ionizing radiation exposure have 
been associated with hypoparathyroidism (36, 37, 38).
6. Mineral deposition
Wilson’s disease with copper deposition in the 
parathyroid glands has been reported to be a cause of 
hypoparathyroidism (39, 40, 41). Hemochromatosis 
is caused by iron overload and can cause 
hypoparathyroidism. Iron overload can also occur with 
repeated transfusions and can develop in individuals 
with thalassemia (42, 43, 44).
7. Transient hypoparathyroidism
Severe burn injuries and acute illness can be associated 
with transient hypoparathyroidism (45, 46).
8. Functional hypoparathyroidism (magnesium 
deficiency or excess)
Both hypomagnesemia and hypermagnesemia can 
impair parathyroid function. Abnormalities in serum 
magnesium require further evaluation and correction 
(Tables 5 and 6). Magnesium is reabsorbed in the kidney 
and absorbed in the bowel in a passive paracellular 
manner (47, 48). Transcellular absorption of Mg+2 occurs 
via the transient receptor potential melastatin subtype 
6 (TRPM6) channels in the bowel and kidney (48). 
Mg+2 can activate the CASR and lower PTH synthesis 
and secretion (49, 50). Activation of the CASR by 
Mg+2 stimulates phospholipase C and A2 and inhibits 
cellular cAMP with inhibition of PTH release (51). Thus, 
high serum magnesium levels can decrease PTH and 
contribute to hypocalcemia. Activation of the CASR in 
the kidneys results in decreased paracellular transport of 
both calcium and magnesium in the kidneys.
Table 5 Causes of low magnesium and drugs used.
Causes of low magnesium
 • Decreased intake
 • Decreased intestinal absorption (malabsorption, short 
bowel syndrome, severe vomitting, diarrhea, steatorrhea)
 • Familial hypomagnesemia with secondary hypocalcemia 
(TRPM6 mutation)
 • Autosomal dominant hypocalcemia (activating mutation in 
CASR gene)
 • Familial hypomagnesemia with hypercalciuria and 
nephrocalcinosis (FHHNC)
Drugs
 • Thiazides, furosemide
 • Proton pump inhibitor
 • Antibiotics
 • Antimycotics (foscarnet, amphotericin B, aminoglycosides, 
pentamidine, rapamycin)
 • Anticancer drugs (cisplatin, carboplatin)
 • Immunosuppressants (calcineurin inhibitors-tacrolimus, 
cyclosporine A)
 • EGF-receptor inhibitors (cetuximab)
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Activating mutations of the CASR result in ADH with 
hypocalcemia as well as hypomagnesemia in a significant 
number of patients (52).
Mutations in the claudin proteins (claudin 16 and 19) 
impair paracellular renal reabsorption of both calcium 
and magnesium causing familial hypomagnesemia 
with hypercalciuria and nephrocalcinosis (FHHNC) 
(52, 53, 54).
Loss-of-function mutations in TRPM6 channels 
affect active transcellular Mg+2 transportation in both 
the kidney and the bowel and result in hypomagnesemia 
with secondary hypocalcemia (HSH) (55, 56). Severe 
hypomagnesemia blocks PTH synthesis and secretion by 
increasing inhibitory G alpha subunit activity (57).
A resistance to PTH at the skeletal level is also seen 
in hypomagnesemia as intracellular Mg+2 is a cofactor 
of adenylate cyclase and decreases in intracellular 
Mg+2 lead to a resistance to PTH (57). Magnesium 
plays a key role in calcium homeostasis and should be 
evaluated and normalized. A more accurate assessment 
of magnesium stores can be obtained by measuring 
the red blood cell magnesium (47). In the presence 
of hypomagnesemia assessing urinary magnesium 
can be helpful. Measuring the fractional excretion of 
magnesium enables differentiation of renal magnesium 
losses from intestinal losses (FEMg = urine Mg × plasma 
Cr/0.7 × plasma Mg × urine creatinine × 100%). If FEMg 
>4% in the presence of hypomagnesemia, this would be 
consistent with renal magnesium wasting (58). An extra 
renal cause of magnesium loss is likely to be present if 
FEMg <2% (58).
9. Mitochondrial disorders associated 
with hypoparathyroidism
Kearns–Sayer syndrome is characterized by opthalmoplegia 
ptosis, retinitis pigmentosa, cardiomyopathy, cardiac 
conduction blocks as well as ataxia.
Mitochondrial myopathy, encephalopathy, lactic 
acidosis, stroke-like episodes (MELAS) syndrome presents 
with muscle weakness and affects the central nervous 
system (59, 60).
10. Maternal hyperparathyroidism
Infants exposed in utero to maternal primary 
hyperparathyroidism may develop suppressed parathyroid 
function and hypocalcemia (61, 62, 63).
PTH resistance syndromes
Pseudohypoparathyroidism (PHP) is characterized by 
target organ resistance to PTH. The biochemical profile is 
the same as seen in hypoparathyroidism with low serum 
calcium and high phosphate; however, PTH levels are 
elevated. PHP type 1 is associated with maternal loss of 
function mutations in the GNAS1 gene, which encodes 
the alpha subunit of the stimulatory G protein (Gsa) 
coupled to the PTH receptor. These mutations result in 
the inability of the G protein to activate adenylate cyclase 
upon binding of PTH to its receptor leading to failure of 
signal transduction to produce an end-organ response to 
PTH (64). The manifestations of PHP depend on whether 
the mutation is maternally or paternally transmitted (65) 
(Table 3).
PHP type 1a (GNAS1 mutation on maternally inherited allele)
The clinical features of PHP type 1a include Albright 
hereditary osteodystrophy (AHO) – which refers to a 
constellation of developmental and skeletal defects, 
which include short stature, obesity, dental hypoplasia, 
mental retardation, frontal bossing, short neck, round 
face, subcutaneous calcification, shortened fourth and 
fifth metacarpals and metatarsals (brachydactyly) and 
developmental delay. Resistance to other G-protein-
coupled hormones may be present including 
gonadotropins, TSH and GHRH (66, 67). The biochemical 
profile demonstrates low calcium, high phosphate and 
high PTH.
PHP 1b (GNAS1 mutation or STX gene mutation)
This condition is associated with a mutation in the cis-
acting element of GNAS1 resulting in reduction or complete 
absence of alpha subunit of stimulatory G protein in the 
proximal renal tubules. The PTH resistance is confined to 
the kidney (68, 69). There are no clinical features of AHO. 
The biochemical profile demonstrates PTH resistance with 
low calcium, high phosphate and high PTH. Usually there 
is no resistance to other hormones.
Table 6 Causes of high serum magnesium.
 • Chronic kidney disease
 • Familial hypocalciuric hypercalcemia
 • Excess intake (cathartics, laxatives, parenteral Mg+2)
 • Tocolytic therapy for eclampsia
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PHP1c (GNAS mutation on maternally inherited allele)
Clinical features of AHO are present as well as resistance 
to PTH and other hormones.
The GNAS1 mutation affects coupling of G proteins to 
the PTH receptor. Gsa is normal in quantity and activity, 
ability to stimulate adenylate cyclase is intact (70).
Pseudo-PHP (GNAS mutation on paternally inherited alleles)
This condition is secondary to paternally transmitted 
inactivating GNAS1 mutation. AHO is present without 
the renal tubular resistance to PTH. The paternal allele of 
GNAS1 is always silenced due to genetic imprinting and 
if the maternal allele is normal, the biochemical profile is 
normal (71). Laboratory profile includes normal calcium, 
phosphate and PTH.
Progressive osseous heteroplasia
A paternally inherited inactivating mutation in the 
GNAS1 gene results in progressive osseous heteroplasia 
(72). The clinical features include extensive ectopic bone 
formation in the skin, muscles and connective tissues as 
well as AHO. Laboratory profile includes normal calcium, 
phosphate and PTH.
Idiopathic
If the cause of the hypoparathyroidism is not identified 
following a careful clinical and laboratory evaluation, the 
condition can be confirmed as idiopathic in etiology.
Key points:
The diagnosis of hypoparathyroidism is made in the 
presence of low serum calcium (ionized or adjusted 
for albumin) and low or inappropriately normal PTH 
confirmed on two separate occasions. Further evaluation 
enables identification of the cause of hypoparathyroidism 
in nonsurgical cases. In young individuals or 
consanguineous parents a referral to a geneticist is advised 
for appropriate genetic counseling. DNA studies enable a 
molecular diagnosis to be made.
Quality of evidence: low.
(b) How do we evaluate target organ damage in 
hypoparathyroidism?
Hypercalciuria is commonly seen in chronic 
hypoparathyroidism on treatment, and may lead to 
nephrocalcinosis, nephrolithiasis and renal insufficiency. 
Renal complications are assessed by regular monitoring 
of renal function (eGFR and serum creatinine) as well as 
assessment for hypercalciuria with a 24-h urine calcium 
and creatinine assessment (5, 73, 74, 75). Renal imaging 
with ultrasound is recommended with identification of 
nephrocalcinosis or nephrolithiasis (76, 77). If ocular 
complications (posterior subcapsular cataracts) are 
suspected, a slit lamp examination is performed (5, 
73, 74). The development of neurocognitive decline, 
movement disorders or seizures may indicate brain 
calcification, which are evaluated by brain imaging and an 
electroencephalogram. In the absence of these symptoms, 
the role of brain imaging to monitor these complications 
is unclear.
Key points:
The risk for and extent of renal complications are assessed 
by evaluating renal function (eGFR), a 24-h urine for 
calcium excretion, and a renal ultrasound for the presence 
of nephrocalcinosis or nephrolithiasis. Brain imaging 
is advised in the presence of cognitive impairment, 
movement disorders or seizures. Opthalmoscopic 
examination enables assessment for the development 
of cataracts and can be completed in the presence of 
symptoms or concerns.
Quality of evidence: low.
(c) How frequently should biochemical and clinical 
assessment be performed?
Current consensus supports regular monitoring of 
(a) serum chemistries including calcium corrected for 
albumin (or ionized calcium), phosphorus, magnesium, 
urea nitrogen and creatinine every 3–6  months; (b) 
urinary calcium excretion, creatinine and sodium (either 
by 24-h urine collection or random urine collection) 
and 25-hydroxyvitamin D levels (annually); (c) renal 
calcification by imaging, such as ultrasound, if there 
is persistent hypercalciuria, a history of renal stones, 
abnormal urinalysis or a decline in eGFR; (d) signs and 
symptoms of hypocalcemia and hypercalcemia should 
be evaluated every 6  months based on the stability of 
hypoparathyroidism. Asking the patient regarding their 
overall function is also of value as many symptoms of 
hypoparathyroidism are nonspecific and include low 
energy or fatigue or brain fog and may be a marker of poor 
serum calcium control and (e) basal ganglia calcification 
can be evaluated with brain CT or susceptibility-weighted 
MRI (SW-MRI) and the presence of cataracts as part of 
the routine annual eye examination. The serum calcium 
and phosphate may require closer monitoring (every 
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1–2 weeks) if changes are made in the dose of the calcium 
or active vitamin D or if symptoms are present.
Key points:
Serum and urine biochemistries should be evaluated at 
least every 6  months for calcium (ionized or albumin-
adjusted), phosphate, magnesium, 25-hydroxyvitamin 
D and annually for 24-h urine calcium and creatinine. 
Following changes in the dose of calcium or active vitamin 
D the lab profile should be repeated in 1–2 weeks.
Quality of evidence: low.
2. Management of hypoparathyroidism – 
avoiding complications of treatment
(a) Are long-term complications a real problem?
Long-term complications include renal impairment, 
renal stones, nephrocalcinosis as well as cataracts and 
calcification of the basal ganglia and other regions of 
the brain (5). Several retrospective studies have shown 
that long-term complications of hypoparathyroidism are 
commonly seen. A large cohort study determined the 
rate of complications in 120 patients with permanent 
hypoparathyroidism with a mean follow-up of 7.4 years 
(75). While serum calcium levels were maintained within 
a calcium range of 7.5–9.5 mg/dL (1.9–2.4 mmol/L) for 
an average of 86% of the time, the 24-h urinary calcium 
analysis in 53 patients showed that 38% had a least one 
measurement with hypercalciuria (>300 mg/day). Renal 
imaging in 54 patients showed renal calcification was 
present in 31% of the patient population. Compared 
with age-appropriate historical controls from NHANES, 
the rates of chronic kidney disease stage 3 or higher were 
2- to 17-fold greater in those with hypoparathyroidism. 
These data have been recently confirmed in another 
series of 90 patients with chronic post-surgical 
hypoparathyroidism (6).
In a large case–control study from a national registry 
in Denmark, the hazard ratio (HR) for developing kidney 
stones and renal insufficiency in patients with post-
surgical hypoparathyroidism was 4.8 and 3.1, respectively 
(78). In another Danish case–control study, the HR 
in patients with nonsurgical hypoparathyroidism for 
developing renal insufficiency was 6.0 (79).
Cataracts have been reported in approximately 
50% of patients with chronic hypoparathyroidism 
in case series (80, 81). In the case–control studies 
from Denmark, the risk of cataracts was increased 
in patients with nonsurgical hypoparathyroidism 
(HR 4.32) (79), but not in patients with post-surgical 
hypoparathyroidism (78).
Intracranial calcifications, in particular in the basal 
ganglia, can develop in patients with hypoparathyroidism 
(75, 82). The exact cause is not known, however, elevated 
serum phosphate levels or an elevated calcium-phosphate 
product are thought to be a contributing factor. The 
clinical significance of basal ganglia calcifications is 
unclear; symptoms of Parkinsonism and dystonia have 
also been described in some cases (82).
Serum phosphate and the calcium-phosphate product 
should be maintained in the normal reference range (i.e. 
less than 55 mg2/dL2 (4.4 mmol2 L2)) as they are thought 
to contribute to extraskeletal calcifications and other 
complications when elevated (73, 83, 84). This does 
however require further prospective evaluation. If serum 
phosphate levels are high, calcium supplements can be 
increased and should be given with meals as they are 
excellent phosphate binders. The calcium-phosphate 
product may not correlate with basal ganglia calcification 
and this requires further prospective evaluation as well as 
other measures including serum phosphate and the 24-h 
urine calcium, which may be of value in predicting the 
presence of extraskeletal calcification (85). The dose of 
the active vitamin D can also be reassessed as 1,25(OH)2 
increases intestinal calcium absorption as well as 
phosphorus absorption. Dietary modification with a low 
phosphate diet (low intake of meat, eggs, cola and dairy) 
may be implemented as needed on an individual basis. 
A low-salt diet is also helpful as it lowers renal calcium 
losses.
Key points:
In hypoparathyroidism, long-term renal complications 
and extraskeletal calcification are commonly seen and 
may be reduced by lowering urine calcium excretion, 
serum phosphorus and the calcium-phosphate product.
Quality of evidence: very low.
(b) How should acute hypocalcemia be managed?
Depending on the rate of onset, biochemical severity 
and clinical symptoms, acute hypocalcemia may require 
management in hospital with intravenous calcium. 
Calcium gluconate is the preferred salt to be administered 
intravenously as it is less irritating to the veins than calcium 
chloride. A bolus of 1–2 g of 10% calcium gluconate 
(corresponding to 90–180 mg of elemental calcium) in 
50 mL of 5% dextrose may be administered over 20 min 
followed by a continuous infusion of intravenous calcium 
with 1–3 mg/kg/h of elemental calcium administered as 
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calcium gluconate. During the calcium bolus and infusion 
continuous cardiac monitoring is advised. Oral calcium 
supplements and active vitamin D are also initiated (83, 
86). Hypomagnesemia should be corrected (83) and 
vitamin D levels should be normalized (2, 3). Low serum 
magnesium leads to further suppression of PTH synthesis 
and secretion (87). This paradoxical inhibition of the 
parathyroid involves intracellular signaling pathways of 
the CaSR with an increase in the activity of inhibitory 
G alpha subunits (57). Hypomagnesemia also results 
in a resistance to the effects of PTH in the tissues. PTH-
induced bone resorption is impaired in hypomagnesemia 
(88, 89, 90). Intracellular Mg2+ is a cofactor of adenylate 
cyclase and decreases in intracellular ionized Mg2+ lead to 
resistance to PTH (91, 92, 93). Hypocalcemia combined 
with magnesium deficiency is resistant to treatment 
with Ca2+ or vitamin D, but rapidly responds to Mg2+ 
supplementation.
There are very little data (largely from case 
reports) regarding the possible use of rhPTH (1–84) 
in the management of acute hypocalcemia (94, 95, 
96). Hypoparathyroidism is associated with impaired 
hydroxylation of 25 hydroxyvitamin D in the kidney as 
PTH stimulates the formation of 1,25 dihydroxyvitamin 
D (calcitriol) (97). Therefore, individuals with 
hypoparathyroidism have a deficiency of both PTH as well 
as calcitriol. Active vitamin D metabolites are necessary 
to correct the hypocalcemia and enhance the intestinal 
absorption of both calcium and phosphate. Calcitriol can 
be initiated with doses of 0.25 µg twice daily and gradually 
titrated upward to a dose of 2.0 µg BID if necessary (2). 
Occasionally higher doses may be necessary. The half-
life of calcitriol is 5–8 h and the dose can be increased in 
48–72 h. Alfacalcidiol (1alpha (OH) D3) can also be used 
in doses of 0.5–4 µg once daily; however, it has a longer 
time to offset of action (5–7 days) and is not as potent 
as calcitriol (98, 99). Close titration is required to avoid 
hypercalciuria and hypercalcemia which may contribute 
to the long-term complications of renal and extra skeletal 
calcification. Parent vitamin D (D2 or ergocalciferol 
or D3 cholecalciferol) is of value to ensure that the 
25hydroxyvitamin D levels are in the normal reference 
range (75 nmol/L or higher) (100).
Key recommendation:
Acute severe hypocalcemia is treated with IV calcium 
boluses followed by a continuous calcium infusion as 
well as oral calcium supplements and active vitamin D. 
Hypomagnesemia must be corrected.
Quality of evidence: low (standard practice).
(c) What are practical strategies to lower urinary calcium?
Reducing the filtered renal load of calcium by decreasing 
serum calcium is the most effective method to lower 
urinary calcium in chronic hypoparathyroidism. 
Thiazide diuretics may also be effective in lowering 
urinary calcium losses especially when combined with 
a low-salt diet (101). For individuals with ADH type 
1 (ADH 1) and ADH 2, thiazide diuretics may further 
exacerbate the hypokalemia; therefore, extreme caution 
must be exercised. Distributing calcium supplements 
evenly throughout the day can avoid peaks of serum 
calcium, which may contribute to hypercalciuria. Finally, 
rhPTH(1–84) replacement therapy may also be considered 
as discussed below (74).
Key recommendation:
Reduce urinary calcium losses with a low-salt diet 
and consider hydrocholorothiazide, chlorthalidone 
or indapamide as tolerated. In the presence of renal 
complications rhPTH(1–84) may also be considered.
Quality of evidence: low.
3. Management of hypoparathyroidism in 
pregnancy and lactation
(a) What are the physiologic changes in serum calcium 
and the calcium-regulating hormones during pregnancy?
During pregnancy, calcium requirements increase in 
order to meet the growing needs of the developing fetal 
skeleton (102, 103). Approximately 80% of the calcium, 
phosphorus and magnesium present in the full-term fetal 
skeleton is accreted during the 3rd trimester (102).
In pregnancy, the intravascular volume expands 
and with hemodilution, the serum albumin decreases 
resulting in a low total serum calcium (104, 105). The 
ionized calcium, as well as the albumin-corrected total 
calcium level remains unchanged in normoparathyroid 
mothers. PTH-related protein (PTHrP) begins to rise in the 
3rd to the 13th week of gestation reaching a three-fold 
increase in PTHrP levels by term (106, 107, 108, 109). The 
source of the PTHrP is the placenta and breasts, as well as 
the uterus (110, 111, 112).
The lactating breast produces significant levels of 
PTHrP, which is released into the maternal circulation 
and enhances renal calcium reabsorption and phosphate 
excretion as well as bone resorption. PTHrP stimulates 
Cyp27b1 with increased production of calcitriol, which 
in turn enhances intestinal calcium and phosphate 
absorption (113, 114, 115).
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Calcitriol rises in the first trimester and increases 
two- to three-fold by term as observed in longitudinal 
studies (106, 116, 117, 118, 119, 120). Longitudinal 
studies have confirmed a rise in both free and bound 
calcitriol (106, 116, 118). Vitamin D-binding proteins rise 
by approximately 20–40% during pregnancy and the free 
and bound calcitriol rises by two- to three-fold resulting 
in enhanced intestinal calcium and phosphate and 
enable the mother to achieve a positive calcium balance 
in the first trimester (102). The rise in calcitriol increases 
intestinal calcium absorption and suppresses PTH. The 
kidneys are the main source of the calcitriol with possibly 
some contribution from other tissues including the 
placenta and the fetus. Renal expression of Cyp27b1 is 
35-fold higher in maternal kidneys than in the placenta 
(121). Anephric women on dialysis have low calcitriol 
levels during pregnancy (122). However, the factors 
that stimulate renal Cyp27b1 are still not clear. PTHrP, 
estradiol and prolactin may stimulate renal Cyp27b1 
during pregnancy. PTHrP is a weak stimulator of Cyp27b1 
in comparison to PTH (123). The 25(OH) D levels are 
stable during pregnancy despite increased conversion to 
calcitriol and transfer to the fetus (102, 124). Calcitriol 
levels fall into the pre-pregnant range during lactation 
and intestinal calcium absorption normalizes (120, 125, 
126, 127, 128, 129). Further prospective evaluation of 
parent and active vitamin D supplementation is required 
in hypoparathyroid pregnant women (130).
PTH is suppressed to low normal or below normal 
levels in the first trimester and reaches mid normal levels 
by term (106, 108, 117, 125, 126, 131, 132). The PTH levels 
are impacted by changes in dietary calcium and vitamin 
D (102, 133). During lactation, PTH levels are suppressed 
or undetectable as noted with the intact PTH assays (102, 
125, 133, 134, 135, 136).
Calcitonin increases during pregnancy and may 
protect the maternal skeleton from demineralization 
(102). The source of calcitonin includes the thyroid C-cells 
as well as the breast and placenta (137, 138). Higher levels 
of estradiol, estrone and estriol may result in increases in 
serum calcitonin (102). During lactation, calcitonin levels 
may be normal or increased (105, 118, 126, 139).
In pregnancy, the hypoparathyroid mother requires 
careful monitoring of serum calcium, phosphate and 
urinary calcium excretion as the physiologic rises in 
calcitriol and PTHrP may lower the requirements for 
calcium and calcitriol during pregnancy. However, case 
reports of hypoparathyroid women requiring higher 
doses of calcium and calcitriol during pregnancy have also 
been published (140, 141, 142, 143). Close monitoring is 
required during pregnancy to ensure that serum calcium 
is maintained in the normal reference range.
Key finding:
Calcium requirements increase during pregnancy due 
to fetal demands; however, due to rises in PTHrP and 
calcitriol, the dose requirements for calcium and active 
vitamin D in hypoparathyroid mothers may decrease. 
However, in some patients, dose requirements may 
increase.
During lactation calcitriol levels normalize. PTHrP 
levels are high and increase bone resorption and 
enhance renal calcium reabsorption. These effects may 
lower the dose requirements for calcitriol and calcium 
supplementation during lactation in hypoparathyroid 
patients.
Quality of evidence: low.
(b) What are the treatment targets for serum calcium 
during pregnancy?
As calcium requirements increase during pregnancy 
it is important to ensure that the hypoparathyroid 
mother is receiving adequate calcium and calcitriol 
supplementation and is not hypocalcemic as 
this can result in the development of secondary 
hyperparathyroidism in the fetus with fetal skeletal 
demineralization. In contrast, if the mother is 
hypercalcemic the fetal parathyroid tissue may become 
suppressed and the neonate may develop hypocalcemia. 
It is important to closely monitor patients in order 
to avoid hypocalcemia and hypercalcemia. Uterine 
irritability increases with hypocalcemia, and this may 
increase the risk of preterm labor (144).
It is recommended that the total calcium corrected for 
albumin be maintained in the low to mid normal reference 
range and this should be evaluated every 3 weeks during 
pregnancy or more frequently if changes in the calcium 
supplements or calcitriol dose are being made.
Key recommendation:
Serum calcium (corrected or ionized) should be maintained 
in mid-to-low normal reference range. Serum calcium, 
phosphorus, eGFR and magnesium should be monitored 
during pregnancy every 3 weeks. If changes in the dose of 
calcium or calcitriol are recommended, repeat the serum 
calcium in 1–2  weeks. Maintain the 25-hydroxyvitamin 
D and 24-h urine calcium in the normal reference range.
Quality of evidence: very low.
(c) How should management be modified to reduce the 
risk of maternal and fetal complications?
Eu
ro
pe
an
 Jo
ur
na
l o
f E
nd
oc
ri
no
lo
gy
180:3 P12Consensus Statement A A Khan and others Diagnosis and management of 
hypoparathyroidism
https://eje.bioscientifica.com
Close monitoring of circulating levels of calcium corrected 
for albumin, phosphate and magnesium is necessary to 
avoid complications of hypoparathyroidism in pregnancy. 
Uterine irritability increases with hypocalcemia and 
may increase risk of preterm labor or miscarriage (144). 
Ensure that the mother is receiving adequate calcium and 
calcitriol supplementation to maintain the serum calcium 
in the normal reference range. Neonatal complications 
include small for gestational age and respiratory distress 
syndrome (140, 145, 146, 147, 148).
A recent retrospective audit of an Australian database of 
ten pregnancies with hypoparathyroidism demonstrated 
that the requirements for calcitriol vary during the second 
half of pregnancy and decrease substantially during 
lactation (148, 149).
Hydrochlorothiazide should be avoided during 
pregnancy as it is classified as an FDA pregnancy risk 
category B drug (150). PTH has not been adequately 
evaluated in pregnancy. It is classified as an FDA pregnancy 
risk category C drug. A case of one patient treated with 
PTH(1–34) has been reported and the neonate was normal 
at birth with normal serum calcium (151). The dose of the 
calcitriol can be adjusted based on the serum ionized or 
albumin-adjusted calcium with close monitoring during 
pregnancy every 2–3 weeks for serum calcium (albumin-
adjusted or ionized) phosphorus and magnesium. The 
25-hydroxyvitamin D level should be normalized (75–
125 nmol/L (30–50 ng/mL) (152).
During lactation, monitoring can continue every 
4 weeks. Both pregnant and lactating women should be 
informed of the symptoms of hypo- and hypercalcemia 
(Table 7) and advised to immediately check their serum 
calcium if they are not well and seek urgent medical 
assistance as needed. Care must be co-ordinated between 
the treating endocrinologist as well as the obstetrician 
and the pediatrician to ensure optimal maternal and fetal 
outcomes.
Key recommendation:
Discontinue thiazide diuretics during pregnancy, adjust 
the dose of calcium and active vitamin D targeting low-
to-mid normal albumin-corrected calcium. Advise the 
pediatrician to assess the neonate immediately following 
birth and monitor serum calcium. During lactation 
continue to monitor serum calcium every 4  weeks and 
adjust the dose of the calcium and calcitriol supplements 
targeting mid-to-low normal serum calcium.
Quality of evidence: very low.
4. rhPTH(1–84) replacement therapy in 
hypoparathyroidism – when and how 
to proceed?
A number of key questions arise when considering 
which patients with chronic hypoparathyroidism should 
be treated with rhPTH(1–84) replacement therapy. 
Replacement therapy with rhPTH(1–84) has been 
approved as an adjunct to conventional therapy by 
regulatory agencies.
(a) Which criteria confirm that conventional therapy for 
chronic hypoparathyroidism has failed?
Limitations of conventional therapy with calcium, 
active vitamin D metabolites and vitamin D include 
an inability to alleviate the symptoms of hypocalcemia 
and to improve quality of life. In the absence of PTH, 
urinary calcium excretion is elevated and contributes 
to the long-term complications of hypoparathyroidism 
which include renal insufficiency, nephrocalcinosis as 
well as nephrolithiasis (153). Guidelines define failure of 
conventional treatment of chronic hypoparathyroidism 
as meeting certain criteria (73, 74): (1) inability to keep 
serum calcium in the lower half of reference range 
without symptoms of hypocalcemia, (2) failure to keep 
serum phosphate within the reference range, (3) inability 
to keep the calcium-phosphorus product below 55 mg2/
dL2 (4.4 mmol2 L2), (4) failure to keep serum magnesium 
within the reference range, (5) inability to keep urinary 
calcium within the reference range for weight and gender 
and 6) failure to maintain long-term well-being and QOL.
In addition, compliance with conventional therapy is 
often poor and is contributed to by the large number of 
pills required daily as well as gastrointestinal side effects 
of supplemental calcium.
Key recommendation:
Failure of conventional therapy is confirmed in the 
presence of poor control of serum calcium, the presence 
of complications of hypoparathyroidism or the presence 
of a poor quality of life.
Table 7 Symptoms of hypocalcemia and hypercalcemia.
Hypocalcemia Numbness, tingling in face, hands and feet, muscle spasm, cramps, depression, confusion, seizures, 
bradyarrhythmia, wheezing, laryngospasm, congestive heart failure
Hypercalcemia Polydipsia, polyuria, nausea, anorexia, vomiting, constipation, weakness, headaches, confusion
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Quality of evidence: low-moderate.
(b) When should rhPTH(1–84) replacement therapy be 
considered in patients with chronic hypoparathyroidism?
PTH replacement therapy was initially evaluated in 
hypoparathyroidism with the PTH(1–34) molecule. 
Subcutaneous twice daily injections of PTH(1–34) 
maintained mean urine calcium in the normal range, with 
no difference compared to calcitriol (154, 155), whereas 
intravenous administration using a pump resulted in a 
marked decline in mean urine calcium well within the 
normal range, with a significant difference in comparison 
to calcitriol (156). More recently, PTH(1–34) in doses of 
20 µg BID led to reductions in the dose of calcium and 
calcitriol required daily and increased serum calcium 
while lowering serum phosphate (157, 158) (Table 8).
Replacement therapy with PTH(1–84) maintains 
serum calcium and phosphate levels in the appropriate 
range, while reducing the daily doses of calcium and active 
vitamin D metabolites (159, 160). In some patients PTH 
replacement therapy enables withdrawal of calcium and 
active vitamin D analogs. The effects on urinary calcium 
excretion are modest; however, a long-term open-label 
study suggests a progressive decrease in urinary calcium 
excretion (161) (Table  8). Skeletal abnormalities (low 
turnover status, increased bone mineral density (BMD)) 
are improved. Bone turnover markers increase within 
1 year and subsequently decline to levels that are higher 
than pretreatment values. BMD increases at the lumbar 
spine and to a lesser extent at the hip, while there is a 
progressive decline at the distal 1/3 radius (161). Bone 
histomorphometry studies have shown reductions in 
trabecular width and an increase in trabecular number. 
Intratrabecular tunneling has been demonstrated in 
about half of the biopsy specimens (161). Cancellous 
bone matrix mineralization is markedly increased in 
hypoparathyroid bone compared to normal. rhPTH(1–84) 
treatment after 1 year is associated with a decrease in the 
degree of mineralization which returns to the baseline 
value at year 2 (162). Conversely, the greater heterogeneity 
detected at 1 year persists (162).
Recently, an increased rate of vertebral fractures 
has been reported in patients with idiopathic 
hypoparathyroidism treated with conventional therapy 
(81). Replacement therapy with rhPTH(1–84) may have 
positive skeletal effects on bone strength and fracture risk; 
however, this requires further evaluation (Table 9).
Several studies have shown that quality of life is 
reduced in patients with hypoparathyroidism (163, 164, 
165, 166). Short-term placebo-controlled studies have 
shown either no effect or modest improvement, whereas 
a long-term open-label study has shown a benefit in all 
parameters of the SF-36 scale (163).
PTH replacement therapy is well tolerated and adverse 
events are mild and transient.
No data are currently available on the potential 
long-term benefits of rhPTH(1–84) replacement therapy. 
The FDA has approved rhPTH(1–84) with a ‘black box’ 
warning because of an increased risk of osteosarcoma in 
rats treated with high doses of PTH(1–34); however, an 
increased rate of osteosarcoma has not been observed in 
humans despite use in more than a million people (167).
As PTH therapy in hypoparathyroidism has been 
demonstrated to lower the requirements for calcium and 
active vitamin D analogs and also lower serum phosphate 
as well in some studies demonstrated reductions urinary 
calcium excretion, it has been proposed that PTH 
replacement be considered in the following circumstances;
1. inadequate control of serum calcium,
2. oral calcium or vitamin D medications required to 
control serum calcium or symptoms that exceed 2.5 g 
calcium or >1.5 μg calcitriol per day,
3. hypercalciuria, renal stones, nephrocalcinosis, stone 
risk or reduced creatinine clearance or eGFR (<60 mL/
min),
4. hyperphosphatemia and/or calcium-phosphate 
product that exceeds 55 mg2 dL2 (4.4 mmol2 L2) (74).
There are many factors contributing to urine calcium 
including the filtered calcium load as well as the dose of 
PTH and frequency of administration of this molecule. 
Further prospective data will enable refinement of 
administration with a goal to consistently reduce urine 
calcium excretion.
PTH replacement may also be of value in individuals 
who have malabsorption or are intolerant of large 
doses of oral calcium supplements as well as those who 
are noncompliant with taking several pills each day. 
PTH replacement therapy may improve quality of life; 
however, effects of PTH replacement on quality of life 
require further study as currently controlled studies have 
not demonstrated reversal of muscle weakness and fatigue 
with therapy. Wide fluctuations in serum calcium may 
occur in certain individuals with hypoparathyroidism 
particularly following exercise or with intercurrent illness 
and may result in hospitalization. Overcorrection of 
hypocalcemia may lead to hypercalcemia and individuals 
with wide fluctuations in serum calcium require close 
monitoring ideally with a calcimeter which can provide 
immediate measures of serum calcium in real time. 
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Having such devices easily available to patients will 
enable assessment of serum calcium with the onset of 
symptoms and allow closer titration of therapy based on 
current serum calcium. Such close monitoring is expected 
to revolutionize care for hypoparathyroidism similar to 
the enhanced care possible for diabetes with the advent 
of glucometers. Calcimeters have been developed and are 
expected to be released for general use in the near future. 
The approved indications for PTH replacement therapy 
may vary depending on the regulatory authorities of each 
country.
Key recommendation:
rhPTH(1–84) replacement therapy may be considered if the 
serum calcium is poorly controlled, high doses of calcium 
or active vitamin D are required, renal complications 
are present or quality of life is poor or gastrointestinal 
malabsorption is present.
Quality of evidence: low.
(c) Once rhPTH(1–84) replacement therapy is started, how 
should therapy be titrated?
The FDA approved starting rhPTH(1–84) at a dose of 
50 µg by subcutaneous injection once each day with a 
concomitant 50% decrease in the dose of active vitamin 
D metabolites (83, 167). After an appropriate interval of 
several weeks, the dose may be increased to 75 µg each 
day, and then 100 µg each day after several more weeks, or 
reduced to 25 µg each day, as required to meet treatment 
goals, aiming to discontinue the active vitamin D and 
reduce calcium supplements to 500 mg daily.
Key recommendation:
rhPTH(1–84) replacement therapy can be initiated at a 
50 µg daily dose with close monitoring of serum calcium 
and phosphate. The dose of rhPTH (1–84) can be gradually 
titrated upwards or downwards based on the lab profile 
and the doses of serum calcium and active vitamin D can 
also be gradually reduced as the dose of the rhPTH(1–84) 
is gradually increased.
Quality of evidence: low-moderate.
(d) If rhPTH(1–84) replacement therapy is initiated, 
should it ever be stopped?
This is left to the judgment of the treating physician. 
rhPTH(1–84) replacement therapy may be stopped if 
treatment goals cannot be achieved despite appropriate 
dose adjustment, or patients are unable to tolerate or 
comply with therapy for any reason. Discontinuation 
of rhPTH(1–84) requires gradual reductions in the dose 
over several weeks as abrupt cessation has been associated Ta
b
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with hypocalcemia, which may reflect increased bone 
remodeling favoring formation leading to the hungry 
bone syndrome (168). While decreasing the rhPTH(1–84) 
dose treatment with active vitamin D metabolites should 
be restarted or adjusted, as appropriate.
Key recommendation:
Stop therapy if the treatment goals cannot be achieved 
despite appropriate dose adjustment or if the patient is 
unable to tolerate or comply with therapy for any reason.
Quality of evidence: low-moderate.
Conclusion
Hypoparathyroidism is a rare condition, which requires 
careful evaluation and timely pharmacologic intervention 
in order to prevent significant morbidity and mortality. 
Frequent laboratory monitoring of the biochemical profile 
and patient education is essential to achieving optimal 
control of serum calcium and potentially lowering the 
risk of long-term complications.
Pregnancy requires close monitoring to ensure that 
the mother maintains a serum calcium in the low normal 
reference range with avoidance of hypercalcemia as well 
as hypocalcemia for optimal maternal and fetal outcomes.
Conventional therapy consists of calcium and 
active vitamin D. PTH replacement therapy has been 
demonstrated to lower the doses of calcium and active 
vitamin D required and may lower the long-term 
complications of hypoparathyroidism.
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